TRAVERE THERAPEUTICS, INC.: 10-Q/A filed 2012-06-06
What TRAVERE THERAPEUTICS, INC. reported in its quarterly report amendment filed 2012-06-06 (fiscal Q2 2011): 9 published measures, 22 facts as tagged in accession 0001225279-12-000084.
This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.
This filing
- Form
- 10-Q/A (quarterly report amendment)
- Filed
- 2012-06-06
- Fiscal period
- fiscal Q2 2011
- Accession
- 0001225279-12-000084 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TRAVERE THERAPEUTICS, INC. filings.
Reported measures
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-02-28 | -60,255 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-06-01 to 2011-08-31 | -3,525 | USD | 92 |
| 2011-03-01 to 2011-08-31 | -7,049 | USD | 184 |
| 2010-06-01 to 2010-08-31 | -6,626 | USD | 92 |
| 2010-03-01 to 2010-08-31 | -13,270 | USD | 184 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-03-01 to 2011-08-31 | -49 | USD | 184 |
| 2010-03-01 to 2010-08-31 | -18 | USD | 184 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-06-01 to 2011-08-31 | 0 | USD | 92 |
| 2011-03-01 to 2011-08-31 | 0 | USD | 184 |
| 2010-06-01 to 2010-08-31 | 0 | USD | 92 |
| 2010-03-01 to 2010-08-31 | 0 | USD | 184 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-02-28 | -121,256 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-06-01 to 2011-08-31 | 500 | USD | 92 |
| 2011-03-01 to 2011-08-31 | 1,000 | USD | 184 |
| 2010-06-01 to 2010-08-31 | 3,626 | USD | 92 |
| 2010-03-01 to 2010-08-31 | 7,252 | USD | 184 |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-02-28 | 60,904 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-02-28 | 64,213 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-06-01 to 2011-08-31 | 3,025 | USD | 92 |
| 2011-03-01 to 2011-08-31 | 6,049 | USD | 184 |
| 2010-06-01 to 2010-08-31 | 3,000 | USD | 92 |
| 2010-03-01 to 2010-08-31 | 6,018 | USD | 184 |
Inspect the source
- Entity
- TRAVERE THERAPEUTICS, INC. / CIK 0001438533
- Captured
- 2026-09-20T09:03:46.664Z
- SEC response SHA-256
b66a9ecfb78fb2c3fc29384fc9ee702340e57ee037364236a402186d866938b6
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001438533.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))